指南与共识银屑病与炎症性皮肤病

中重度银屑病生物制剂治疗持续性的专家共识

Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2019-04-29

本研究采用改良德尔菲法,组织90名皮肤科医生和34名医院药师,就银屑病治疗持续性的定义、影响因素及经济成本等70项内容达成共识。皮肤科医生对77.1%的条目达成共识,药师对71.4%的条目达成共识。双方均认为标准化评估治疗维持很重要,但皮肤科医生认为治疗生存、持续性和保留同义,而药师仅认可治疗持续性为有效术语。

要点

  • 治疗持续性反映长期疗效与安全性,应标准化评估。
  • 药物有效性、安全性及患者满意度影响治疗持续性。
  • 分析持续性时需考虑停药原因,并采用Kaplan-Meier法。

核心结论

  • 德尔菲共识强调皮肤科医生与医院药师对治疗持续性解读存在不同视角,需协调结果。

研究设计与样本

  • 改良德尔菲法,两轮,涉及90名皮肤科医生和34名医院药师,问卷共70项。

主要发现

  • 皮肤科医生对77.1%的条目达成共识,医院药师对71.4%的条目达成共识。
  • 皮肤科医生认为治疗生存、持续性和保留是同义词,而医院药师仅认为治疗持续性为有效术语。
  • 双方均同意治疗持续性受药物有效性、安全性及患者满意度影响,且应作为治疗成功的指标。
  • 双方同意在Kaplan-Meier分析中考虑不同停药原因,且治疗持续性可降低治疗成本。

关键数值与推荐

  • 双方同意使用标准化措施评估治疗维持情况。
  • 皮肤科医生共识:治疗生存、持续性和保留同义;医院药师共识:仅治疗持续性为有效术语。
  • 共识认为药物持续性受有效性、安全性及患者满意度影响。
  • 共识认为不同停药原因应纳入Kaplan-Meier分析。
  • 共识认为治疗持续性可降低治疗成本。

临床怎么用

  • 临床中应采用标准化指标评估生物制剂治疗持续性。
  • 分析持续性时需记录停药原因并应用Kaplan-Meier法。
  • 关注药物有效性、安全性及患者满意度以改善持续性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment persistence is becoming a useful measure to evaluate long-term effectiveness and safety of biological therapies in real-world settings. OBJECTIVE: The main objective of this study was to explore the scientific opinion of a panel of dermatologists and hospital pharmacists to reach a consensus about the impact, causes, and best strategies and interventions that might be associated with improved drug persistence in patients with psoriasis in Spain. METHODS: This research was conducted using a modified Delphi method organized in two rounds and involving a panel of 90 dermatologists and 34 hospital pharmacists. A questionnaire of 70 items was developed. The items proposed to reach a consensus included topics such as definitions and measures in the treatment of psoriasis, analysis of treatment persistence, factors that may influence treatment persistence, impact of treatment persistence and economic cost of treatment. RESULTS: Dermatologists reached a consensus on 77.1% of the items proposed, and hospital pharmacists reached a consensus on 71.4%. Both groups agreed that it is important to use standardized measures in the evaluation of treatment maintenance over time. Dermatologists agreed that treatment survival, persistence and retention are synonymous, but hospital pharmacists considered only treatment persistence as a valid term. In addition, panelists agreed that drug persistence is an indicator of success in the treatment of psoriasis that may be influenced by a drug's effectiveness and safety profile, as well as by patient satisfaction. They agreed that the different causes of treatment discontinuation should be considered in Kaplan-Meier analysis of treatment persistence. Moreover, treatment persistence was agreed to decrease the cost of therapy. CONCLUSION: This Delphi consensus highlights the different perspectives of dermatologists and hospital pharmacists regarding the interpretation of treatment persistence, and the challenge of harmonizing the results obtained.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. de la Cueva Dobao P, Notario J, Ferrándiz C, et al. Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2019. PMID: 31037770. doi:10.1111/jdv.15600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。